Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Double regulatory joy for Bayer and Onyx’ Nexavar
The positive opinion is for Nexavar (sorafenib) 200mg film-coated tablets for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer, who have failed prior
The positive opinion is for Nexavar (sorafenib) 200mg film-coated tablets for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer, who have failed prior
The European submission follows the filing of a biologics license application (BLA) for Cimzia (certolizumab pegol, CDP870) to the FDA on March 1, 2006 and is based on
Drugs aimed at suppressing inflammation-provoking cytokines – specifically those linked to T-cells – have improved the treatment of rheumatoid arthritis (RA), a chronic, inflammatory autoimmune disease. Still, the
Aveo will pay Xoma an up-front license fee, development milestones and royalties. Aveo retains all development and commercialization rights to AV-299. More specific financial terms were not disclosed.
“Our Chimigen vaccine platform is an innovative technology designed to activate a broad immune response against viral infection. HepaVaxx B Vaccine is the first candidate from this platform
Health research and surveillance is vital for the delivery of effective health services and public health interventions, but since the introduction of the Data Protection Act, research has
In a similar way to ovulation suppression by hormone treatment in women, sperm production can be inhibited by androgen or androgen-progestagen treatment combinations in men. With such hormone
Truvada itself is a fixed-dose product that contains two of Gilead’s anti-HIV medications, Viread and Emtriva, in a single once-daily tablet. If approved by the FDA, the new
AZD-103 is part of an emerging class of disease-modifying agents that have the potential to both reduce disease progression and improve symptoms such as cognitive function. This unique
Abraxane, approved by the FDA in January 2005, achieved sales of $134 million in its first 11 months on the market. The drug is currently in various stages